The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Targeting the neurotoxic species in Alzheimer's disease: inhibitors of Aβ oligomerization
Abstract
In the past two decades, a large body of evidence has established a causative role for the β‐amy‐loid peptide (Aβ) in Alzheimer's disease (AD). However, recent debate has focused on whether amyloid fibrils or soluble oligomers of Aβ are the main neurotoxic species that contribute to neurodegeneration and dementia. Considerable early evidence has indicated that amyloid fibrils are toxic, but some recent studies support the notion that Aβ oligomers are the primary neurotoxins. While this crucial aspect of AD pathogenesis remains controversial, effective therapeutic strategies should ideally target both oligomeric and fibrillar species of Aβ. Here, we describe the anti‐amyloido‐genic and neuroprotective actions of some di‐ and tri‐substituted aromatic compounds. Inhibition of the formation of soluble Aβ oligomers was monitored using a specific antibody‐based assay that discriminates between Aβ oligomers and monomers. Thioflavin T and electron microscopy were used to screen for inhibitors of fibril formation. Taken together, these results led to the identification of compounds that more effectively block Aβ oligomerization than fibrillization. It is significant that such compounds completely blocked the neurotoxicity of Aβ to rat hippocampal neurons in culture. These findings provide a basis for the development of novel small molecule Aβ inhibitors with potential applications in AD.—De Felice, F. G., Vieira, M. N. N., Saraiva, L. M., Figueroa‐Villar, J. D., Garcia‐Abreu, J., Liu, R., Chang, L., Klein, W. L., Ferreira, S. T. Targeting the neurotoxic species in Alzheimer's disease: inhibitors of Aβ oligomerization.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alzheimer's Disease Is a Synaptic Failure
Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420
Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291
Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis
Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W., & Glabe, C. G. (2003) · Science · doi:10.1126/science.1079469 · Cited by 4,064
Diffusible, nonfibrillar ligands derived from Aβ 1–42 are potent central nervous system neurotoxins
Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506
Self-citationImmunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160
Caughey, B., & Lansbury, P. T. (2003) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.26.010302.081142 · Cited by 1,650
Production of the Alzheimer Amyloid β Protein by Normal Proteolytic Processing
Shoji, M., Golde, T. E., Ghiso, J., Cheung, T. T., Estus, S., Shaffer, L. M., Cai, X.-D., McKay, D. M., Tintner, R., Frangione, B., et al. (1992) · Science · doi:10.1126/science.1439760 · Cited by 1,447
Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease
Janus, C., Pearson, J., McLaurin, J., Mathews, P. M., Jiang, Y., Schmidt, S. D., Chishti, M. A., Horne, P., Heslin, D., French, J., et al. (2000) · Nature · doi:10.1038/35050110 · Cited by 1,431
Curcumin has potent anti‐amyloidogenic effects for Alzheimer's β‐amyloid fibrils in vitro
Ono, K., Hasegawa, K., Naiki, H., & Yamada, M. (2004) · Journal of Neuroscience Research · doi:10.1002/jnr.20025 · Cited by 1,254
Gong, Y., Chang, L., Viola, K. L., Lacor, P. N., Lambert, M. P., Finch, C. E., Krafft, G. A., & Klein, W. L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1834302100 · Cited by 1,061
Self-citation
Cited by
Amyloid Beta: Structure, Biology and Structure-Based Therapeutic Development
Chen, G.-F., Xu, T.-H., Yan, Y., Zhou, Y.-R., Jiang, Y., Melcher, K., & Xu, H. E. (2017) · Acta Pharmacologica Sinica · doi:10.1038/aps.2017.28 · Cited by 1,965
The Role of Amyloid-β Oligomers in Toxicity, Propagation, and Immunotherapy
Sengupta, U., Nilson, A. N., & Kayed, R. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.03.035 · Cited by 740
Necula, M., Kayed, R., Milton, S., & Glabe, C. G. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m608207200 · Cited by 680
Ferreira, S. T., Lourenco, M. V., Oliveira, M. M., & De Felice, F. G. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00191 · Cited by 373
Self-citationBartolini, M., Bertucci, C., Bolognesi, M. L., Cavalli, A., Melchiorre, C., & Andrisano, V. (2007) · ChemBioChem · doi:10.1002/cbic.200700427 · Cited by 348
Oligomeric Intermediates in Amyloid Formation: Structure Determination and Mechanisms of Toxicity
Fändrich, M. (2012) · Journal of Molecular Biology · doi:10.1016/j.jmb.2012.01.006 · Cited by 340
Reinke, A. A., & Gestwicki, J. E. (2007) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2007.00557.x · Cited by 329
Ariga, T., McDonald, M. P., & Yu, R. K. (2008) · Journal of Lipid Research · doi:10.1194/jlr.r800007-jlr200 · Cited by 318
Xie, Z., Culley, D. J., Dong, Y., Zhang, G., Zhang, B., Moir, R. D., Frosch, M. P., Crosby, G., & Tanzi, R. E. (2008) · Annals of Neurology · doi:10.1002/ana.21548 · Cited by 295
Young, L. M., Saunders, J. C., Mahood, R. A., Revill, C. H., Foster, R. J., Tu, L.-H., Raleigh, D. P., Radford, S. E., & Ashcroft, A. E. (2015) · Nature Chemistry · doi:10.1038/nchem.2129 · Cited by 281
BACE1 inhibitors: Current status and future directions in treating Alzheimer's disease
Moussa‐Pacha, N. M., Abdin, S. M., Omar, H. A., Alniss, H., & Al‐Tel, T. H. (2020) · Medicinal Research Reviews · doi:10.1002/med.21622 · Cited by 274
de Godoy, M. A., Saraiva, L. M., de Carvalho, L. R. P., Vasconcelos-dos-Santos, A., Beiral, H. J. V., Ramos, A. B., Silva, L. R. D. P., Leal, R. B., Monteiro, V. H. S., Braga, C. V., et al. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.807180 · Cited by 214
Self-citationMethylene Blue Inhibits Amyloid Aβ Oligomerization by Promoting Fibrillization
Necula, M., Breydo, L., Milton, S., Kayed, R., van der Veer, W. E., Tone, P., & Glabe, C. G. (2007) · Biochemistry · doi:10.1021/bi700411k · Cited by 213
Pitt, J., Roth, W., Lacor, P., Smith, A. B., Blankenship, M., Velasco, P., De Felice, F., Breslin, P., & Klein, W. L. (2009) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2009.07.018 · Cited by 134
Human apolipoprotein A–I binds amyloid-β and prevents Aβ-induced neurotoxicity
Paula-Lima, A. C., Tricerri, M. A., Brito-Moreira, J., Bomfim, T. R., Oliveira, F. F., Magdesian, M. H., Grinberg, L. T., Panizzutti, R., & Ferreira, S. T. (2009) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2008.12.003 · Cited by 121
Self-citationZinc Lowers Amyloid-β Toxicity by Selectively Precipitating Aggregation Intermediates
Garai, K., Sahoo, B., Kaushalya, S. K., Desai, R., & Maiti, S. (2007) · Biochemistry · doi:10.1021/bi700798b · Cited by 110
Geisler, J. G. (2019) · Cells · doi:10.3390/cells8030280 · Cited by 104
Neurovascular Pathways and Alzheimer Amyloid β-peptide
Zlokovic, B. V., Deane, R., Sallstrom, J., Chow, N., & Miano, J. M. (2006) · Brain Pathology · doi:10.1111/j.1750-3639.2005.tb00103.x · Cited by 104
Amyloid-β Triggers the Release of Neuronal Hexokinase 1 from Mitochondria
Saraiva, L. M., Seixas da Silva, G. S., Galina, A., da-Silva, W. S., Klein, W. L., Ferreira, S. T., & De Felice, F. G. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015230 · Cited by 94
Self-citationLambert, M., Velasco, P., Viola, K., & Klein, W. (2009) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152709787601876 · Cited by 29
Self-citation
Metadata
- Authors
- de Felice, F. G., Vieira, M. N. N., Saraiva, L. M., Figueroa‐Villar, J. D., Garcia‐Abreu, J., Liu, R., Chang, L., Klein, W. L., & Ferreira, S. T.
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2004-09
- Volume
- 18
- Issue
- 12
- Pages
- 1366-1372
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- OpenAlex
- W1493908201
- Cited by
- 194
- References
- 17
- FWCI
- 9.50
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.